The new treatments for T2DM, mainly SGLT2i and GLP1-RA, have changed the CV and renal scenario, as they are able to achieve stricter control objectives with less adverse outcomes, such as hypoglycaemia, while improving weight control and reducing the need for insulin. Here, INS is linked to type 2 diabetes mellitus.